IMCR news

Latest 2 stories · newest Sep 14, 2026

IMCR

Immunocore reaches target enrollment in registrational trial

Immunocore announced it achieved the enrollment goal for the TEBE-AM Phase 3 trial of KIMMTRAK in advanced melanoma. Topline data is expected as early as the end of 2026.

Regulatory Sep 14, 2026 sentiment +0.50 SEC filing ↗

IMCR

Immunocore Reports Q2 2026 Financial Results: KIMMTRAK Sales Up 18%

Immunocore Holdings announced $115.9M in Q2 2026 sales for KIMMTRAK, a 18% year-over-year increase. The company reported improved net income for the H1 and provided updates on Phase 3 clinical trials.

Earnings Aug 6, 2026 sentiment +0.70 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IMCR feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IMCR/newsSTART FREE